October 18, 2016 /

Community Update Call: Sarepta & Summit (October 2016)

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

Community Update Call: Sarepta & Summit (October 2016)

Sarepta Therapeutics and Summit recently announced a license and collaboration agreement, which grants Sarepta the right to commercialize Summit’s utrophin modulators in Europe should they receive approval. This includes ezutromid, which is currently in the Phase 2 PhaseOut DMD trial. PPMD hosted a community update call with Sarepta and Summit on October 10, 2016.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo